Cartesian Therapeutics Statistics
Total Valuation
RNAC has a market cap or net worth of $195.45 million. The enterprise value is $111.70 million.
| Market Cap | 195.45M |
| Enterprise Value | 111.70M |
Important Dates
The next estimated earnings date is Monday, November 9, 2026, before market open.
| Earnings Date | Nov 9, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
RNAC has 30.26 million shares outstanding. The number of shares has increased by 9.55% in one year.
| Current Share Class | 30.26M |
| Shares Outstanding | 30.26M |
| Shares Change (YoY) | +9.55% |
| Shares Change (QoQ) | +11.35% |
| Owned by Insiders (%) | 53.31% |
| Owned by Institutions (%) | 21.55% |
| Float | 11.49M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 133.97 |
| Forward PS | 449.21 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 77.26 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.48
| Current Ratio | 7.48 |
| Quick Ratio | 7.19 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -115.80 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -17.43% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -33.10% |
| Weighted Average Cost of Capital (WACC) | 6.47% |
| Revenue Per Employee | $19,693 |
| Profits Per Employee | -$2.03M |
| Employee Count | 75 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -9.19M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -28.93% in the last 52 weeks. The beta is 0.72, so RNAC's price volatility has been lower than the market average.
| Beta (5Y) | 0.72 |
| 52-Week Price Change | -28.93% |
| 50-Day Moving Average | 7.94 |
| 200-Day Moving Average | 7.66 |
| Relative Strength Index (RSI) | 41.12 |
| Average Volume (20 Days) | 142,571 |
Short Selling Information
The latest short interest is 1.86 million, so 6.13% of the outstanding shares have been sold short.
| Short Interest | 1.86M |
| Short Previous Month | 1.80M |
| Short % of Shares Out | 6.13% |
| Short % of Float | 16.15% |
| Short Ratio (days to cover) | 14.59 |
Income Statement
In the last 12 months, RNAC had revenue of $1.48 million and -$151.89 million in losses. Loss per share was -$5.61.
| Revenue | 1.48M |
| Gross Profit | -66.91M |
| Operating Income | -98.66M |
| Pretax Income | -161.08M |
| Net Income | -151.89M |
| EBITDA | -96.05M |
| EBIT | -98.66M |
| Loss Per Share | -$5.61 |
Balance Sheet
The company has $147.61 million in cash and $63.85 million in debt, with a net cash position of $83.75 million or $2.77 per share.
| Cash & Cash Equivalents | 147.61M |
| Total Debt | 63.85M |
| Net Cash | 83.75M |
| Net Cash Per Share | $2.77 |
| Equity (Book Value) | -125.23M |
| Book Value Per Share | -4.17 |
| Working Capital | 133.07M |
Cash Flow
In the last 12 months, operating cash flow was -$76.53 million and capital expenditures -$2.08 million, giving a free cash flow of -$78.61 million.
| Operating Cash Flow | -76.53M |
| Capital Expenditures | -2.08M |
| Depreciation & Amortization | 2.61M |
| Net Borrowing | 46.03M |
| Free Cash Flow | -78.61M |
| FCF Per Share | -$2.60 |
Margins
| Gross Margin | n/a |
| Operating Margin | -6,679.69% |
| Pretax Margin | -10,906.16% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
RNAC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -9.55% |
| Shareholder Yield | -9.55% |
| Earnings Yield | -86.87% |
| FCF Yield | -39.73% |
Analyst Forecast
The average price target for RNAC is $33.67, which is 421.21% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $33.67 |
| Price Target Difference | 421.21% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | 99.02% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 5, 2024. It was a reverse split with a ratio of 1:30.
| Last Split Date | Apr 5, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:30 |
Scores
RNAC has an Altman Z-Score of -3.93 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.93 |
| Piotroski F-Score | 3 |